Collegium Pharma (COLL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 283,749 | 269,480 | 173,688 | 134,126 | 122,722 |
| Marketable Securities | 41,721 | N/A | N/A | N/A | N/A |
| Receivables | 167,479 | 179,127 | 183,119 | 195,402 | 197,505 |
| Inventories | 26,026 | 32,895 | 46,501 | 64,652 | 77,769 |
| TOTAL | $537,297 | $498,300 | $419,989 | $405,216 | $409,774 |
| Non-Current Assets | |||||
| PPE Net | 18,040 | 18,879 | 19,521 | 19,744 | 19,965 |
| Intangibles | 626,396 | 663,859 | 701,163 | 739,841 | 777,393 |
| Other Non-Current Assets | 32,179 | 33,261 | 33,458 | 36,139 | 38,442 |
| TOTAL | $676,615 | $715,999 | $754,142 | $795,724 | $835,800 |
| Total Assets | $1,213,912 | $1,214,299 | $1,174,131 | $1,200,940 | $1,245,574 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 183,333 | 183,333 | 162,500 | 141,667 | 120,833 |
| Accounts payable and accrued liabilities | 2,420 | 2,992 | 3,494 | 7,637 | 6,627 |
| Accrued Expenses | 248,334 | 225,335 | 266,620 | 264,014 | 286,423 |
| TOTAL | $435,058 | $412,702 | $433,726 | $414,497 | $415,094 |
| Non-Current Liabilities | |||||
| Long Term Debt | 309,898 | 353,769 | 397,578 | 441,258 | 484,853 |
| Other Non-Current Liabilities | 268,151 | 268,095 | 147,985 | 147,991 | 148,015 |
| TOTAL | $578,049 | $621,864 | $545,563 | $589,249 | $632,868 |
| Total Liabilities | $1,013,107 | $1,034,566 | $979,289 | $1,003,746 | $1,047,962 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 34,734 | 34,595 | 34,067 | 33,572 | 34,126 |
| Common Shares | 38 | 38 | 37 | 37 | 37 |
| Retained earnings | -285,763 | -298,770 | -281,344 | -274,145 | -274,602 |
| Other shareholders' equity | 38 | 76 | 76 | -283 | 139 |
| TOTAL | $200,805 | $179,733 | $194,842 | $197,194 | $197,612 |
| Total Liabilities And Equity | $1,213,912 | $1,214,299 | $1,174,131 | $1,200,940 | $1,245,574 |